Return to search

AmorChem invests in a new university gene therapy project

AmorChem has made an investment in a university project that will focus on a new gene therapy to help patients with retinal degeneration.

AmorChem has made an investment in a university project that will focus on a new gene therapy to help patients with retinal degeneration. The fund’s financing will bring together three major research groups from the Research Institute of the McGill University Hospital Centre, the University of Pennsylvania and the University of Southern California. Based in Montreal, AmorChem is an early-stage venture fund that launched in 2011.

Source: Press Release